Introduction Leishmaniasis is an important public health problem in the Americas. A
Cochrane review published in 2009 analyzed 38 randomized controlled trials (RCT). We …

It is important to realize that leishmaniasis guidelines cannot always account for individual
variation among patients. They are not intended to supplant physician judgment with respect …

This review describes the pharmacokinetic properties of the systemically administered
antileishmanial drugs pentavalent antimony, paromomycin, pentamidine, miltefosine and …

Background. Treatment for cutaneous leishmaniasis (CL) with standard pentavalent
antimonial therapy is hampered by cumbersome administration, toxicity, and potential …

The current evidence-base for recommendations on the treatment of cutaneous
leishmaniasis (CL) is generally weak. Systematic reviews have pointed to a general lack of …

Background SSG&PM over 17 days is recommended as first line treatment for visceral
leishmaniasis in eastern Africa, but is painful and requires hospitalization. Combination …

Abstract Objectives Meglumine antimoniate (MA; Glucantime®), the 80‐year‐old first‐line
systemic treatment for all forms of American tegumentary leishmaniasis (ATL) caused by …

Background. Children have a lower response rate to antimonial drugs and higher
elimination rate of antimony (Sb) than adults. Oral miltefosine has not been evaluated for …

Background High frequency of relapse in miltefosine-treated visceral leishmaniasis (VL)
patients in India and Nepal followed up for twelve months. Objective To identify …

Leishmaniasis is one of the six diseases regarded most neglected by World Health
Organization which is predominant in developing countries. Clinically, among the different …